Scribe Therapeutics
David T. is an experienced professional who has held various roles in clinical research and program management at companies such as Scribe Therapeutics, Graphite Bio, and Global Blood Therapeutics. David has also served as a speaker and session chair at the MAGI Clinical Research Conference and as a member of Pfizer's Sickle Cell Advisory Board. David T. holds a Bachelors of Science degree in Exercise Biology from the University of California, Davis.
This person is not in any teams
Scribe Therapeutics
1 followers
Scribe is focused on the engineering, delivery, and development of next-generation CRISPR molecules to rewrite and repair the underlying cause of genetic disorders.